Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial - The Lancet
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction | Circulation
Ontarget
PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:4521239
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial. - ppt download
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin. - ppt video online download
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin. - ppt video online download
Charm | PDF | Heart Failure | Medical Treatments
Results of the CHARM trial program. 52–55 Notes: *p for heterogeneity... | Download Scientific Diagram
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - The Lancet
ACE inhibitors & ARBs in HFpEF — NERDCAT
The Primary Outcome Fails — What Next? | NEJM
![PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3092ad4f375a1465b7d1d3a99b6ec0e96ba95eef/5-Figure1-1.png "PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar")
PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
![PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/44636c2520238a6bf7f2c73b6a8ede4a08468856/3-Figure2-1.png "PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin. - ppt video online download
The Evolution of Heart Failure Management: The Role of Aldosterone
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin. - ppt video online download
CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure - McMurray - 2011 - European Journal of Heart Failure -
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | NEJM
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - The Lancet
Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram
![PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ff2a649ad2496775a497804af4658a751daade79/3-Table3-1.png "PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar
ACE Inhibitor Intolerance
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect
